From theheart.org on Medscape

Coverage from the

American Heart Association (AHA) Scientific Sessions 2021

November 13 - 15, 2021; Virtual

November 13 - 15, 2021 Virtual
  • AHA 2021 Obicetrapib: CETP Inhibitor Impresses in LDL Lowering A new lipid-lowering agent in a class that had been written off by many is being developed by a group of academic experts, with new data showing large LDL reductions on top of high-intensity statins.
  • AHA 2021 Daily Oral PCSK9 Inhibitor Encouraging in Phase 1 Trials What if the cholesterol-crushing efficacy of current PCSK9 inhibitors came in a pill instead of a syringe? That's one possibility for a Merck agent in the earliest stages of human trials.
  • AHA 2021 ACEI, ARBs in COVID-19: Be Aware of Acute Kidney Injury The largest randomized dataset yet of ACE inhibitors and angiotensin receptor blockers in COVID-19 shows reassuring results, but with a potential new link to kidney injury in hospitalized patients.

Conference News

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

News from AHA 2020

Previous Coverage